Pharmaceutical Research

, Volume 33, Issue 11, pp 2763–2776

Optimization of Spray Drying Conditions for Yield, Particle Size and Biological Activity of Thermally Stable Viral Vectors

  • Daniel A. LeClair
  • Emily D. Cranston
  • Zhou Xing
  • Michael R. Thompson
Research Paper

DOI: 10.1007/s11095-016-2003-4

Cite this article as:
LeClair, D.A., Cranston, E.D., Xing, Z. et al. Pharm Res (2016) 33: 2763. doi:10.1007/s11095-016-2003-4

Abstract

Purpose

This work examines the relevance of viral activity in the optimization of spray drying process parameters for the development of thermally stable vaccine powders. In some instances, the actual active pharmaceutical ingredient (API) is not included in the process optimization as it is deemed too costly to use until the final selection of operating conditions, however, that approach is inappropriate for highly labile biopharmaceutics. We investigate the effects of spray drying parameters on i) yield, ii) particle size and iii) viral vector activity of a mannitol/dextran encapsulated recombinant human type 5 adenoviral vector vaccine, to demonstrate the effects and magnitude of each effect on the three responses, and further show that the API must be included earlier in the optimization.

Methods

A design of experiments approach was used with response surface methodology (RSM) to optimize parameters including inlet temperature, spray gas flow rate, liquid feed rate and solute concentration in the feed.

Results

In general, good conditions for maintaining viral activity led to reduced yield and fewer particles of the desired size. Within the range of parameters tested, the yield varied from 50 to 90%, the percentage of ideally size particles was 10–50%, and the viral vector titre loss was 0.25–4.0 log loss.

Conclusions

RSM indicates that the most significant spray drying parameters are the inlet temperature and spray gas flow rate. It was not possible to optimize all three output variables with one set of parameters, indicating that there will only be one dominant criteria for processing which in the case of viral vaccines will likely be viral vector activity.

KEY WORDS

adenovirus optimization particle size process parameters spray dry surface response methodology titre viral vector yield 

Abbreviations

AdHu5LacZ

Recombinant human type 5 adenoviral vector expressing Escherichia coli β-galactosidase

API

Active pharmaceutical ingredient

F

Liquid feed rate

F1-5μm

Percentage of particles suitable for dry powder inhalation (1 - 5 μm size)

Mr

Relative molecular mass

Pe

Peclet number

RSM

Response surface methodology

S

Solute concentration in the liquid feed

SEM

Scanning electron microscopy

SG

Spray gas flow rate

T

Titre log loss

TE

Inlet temperature

Tg

Glass transition temperature

We

Weber number

Y

Powder yield

Supplementary material

11095_2016_2003_MOESM1_ESM.docx (588 kb)
Figure S1(DOCX 587 kb)
11095_2016_2003_MOESM2_ESM.docx (583 kb)
Figure S2(DOCX 583 kb)
11095_2016_2003_MOESM3_ESM.docx (585 kb)
Figure S3(DOCX 584 kb)
11095_2016_2003_MOESM4_ESM.docx (197 kb)
Figure S4(DOCX 197 kb)

Funding information

Funder NameGrant NumberFunding Note
Canadian Institutes of Health Research
  • CPG-127775

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Daniel A. LeClair
    • 1
  • Emily D. Cranston
    • 1
  • Zhou Xing
    • 2
  • Michael R. Thompson
    • 1
  1. 1.Department of Chemical EngineeringMcMaster UniversityHamiltonCanada
  2. 2.McMaster Immunology Research Centre & Department of Pathology and Molecular MedicineMcMaster UniversityHamiltonCanada

Personalised recommendations